Yahoo
    Shanghai - Delayed Quote CNY

    InnoCare Pharma Limited (688428.SS)

    26.44 +0.22 (+0.84%)
    At close: 3:00:02 PM GMT+8
    Loading Chart for 688428.SS
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    InnoCare Announces First Patient Dosed in Head-to-Head Registrational Phase III Trial of Mesutoclax with Azacitidine versus Venetoclax with Azacitidine in Treatment Naive AML in China

    InnoCare Announces First Patient Dosed in Head-to-Head Registrational Phase III Trial of Mesutoclax with Azacitidine versus Venetoclax with Azacitidine in Treatment Naive AML in China
    GlobeNewswire 8h ago
    2026 ASH Oral Presentation | InnoCare Announces Phase III Results of Orelabrutinib in ITP Study Meet Primary Endpoint

    2026 ASH Oral Presentation | InnoCare Announces Phase III Results of Orelabrutinib in ITP Study Meet Primary Endpoint
    GlobeNewswire 3d ago
    InnoCare Announces First Subject Dosed in Clinical Trial of TL1A/IL-23p19 Bispecific Antibody ICP-B161 in China

    InnoCare Announces First Subject Dosed in Clinical Trial of TL1A/IL-23p19 Bispecific Antibody ICP-B161 in China
    GlobeNewswire 10d ago
    InnoCare Pharma (SEHK:9969) Stock Shrugs Off Q3 Earnings Turnaround

    InnoCare Pharma (SEHK:9969) Stock Shrugs Off Q3 Earnings Turnaround
    Simply Wall St. 13d ago
    InnoCare Reports 2026 Q3 Results, Sustained Profitability and Accelerating Globalization

    InnoCare Reports 2026 Q3 Results, Sustained Profitability and Accelerating Globalization
    GlobeNewswire 13d ago
    InnoCare Announces Approval of Registrational Phase III Trial of Mesutoclax in Combination with Orelabrutinib in Relapsed/ Refractory MZL in China

    InnoCare Announces Approval of Registrational Phase III Trial of Mesutoclax in Combination with Orelabrutinib in Relapsed/ Refractory MZL in China
    GlobeNewswire 27d ago
    InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China

    InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China
    GlobeNewswire 28d ago
    Is InnoCare Pharma (SEHK:9969) Undervalued On Its Eli Lilly Deal?

    Is InnoCare Pharma (SEHK:9969) Undervalued On Its Eli Lilly Deal?
    Simply Wall St. 1mo ago
    Eli Lilly and InnoCare sign drug discovery deal worth up to $3.35B

    Eli Lilly and InnoCare sign drug discovery deal worth up to $3.35B
    Quartz 1mo ago
    Eli Lilly outlays $3.35bn for secretive drug discovery pact with China’s InnoCare

    Eli Lilly outlays $3.35bn for secretive drug discovery pact with China’s InnoCare
    Pharmaceutical Technology 1mo ago
    InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines

    InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines
    GlobeNewswire 1mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: